Pfizer's strong R&D pipeline, 7.5%+ dividend yield, & undervalued PE ratio make PFE stock a compelling investment opportunity ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Tuesday was a relatively uneventful news day for Pfizer, especially following the pharmaceutical giant's disclosure on Monday ...

Pfizer stock shows strong potential with updates on danuglipron, robust cost controls, and attractive valuations. Learn more ...

Pfizer will end development of weight-loss pill over fears about its impact to the liver - The drugmaker said the patient’s ...

Below is Validea's guru fundamental report for PFIZER INC (PFE). Of the 22 guru strategies we follow, PFE rates highest using our Shareholder Yield Investor model based on the published strategy ...

Activist investor Starboard Value has launched a broadside against Pfizer's leadership under chief executive Albert Bourla, claiming at least $20 billion in value – and possibly as much as $60 ...

Pfizer has announced that it is discontinuing ... We sell different types of products and services to both investment professionals and individual investors. These products and services are ...

Pfizer paid a whopping $1 billion upfront for rights to vepdegestrant (formerly ARV-4710 in 2021 – consisting of $650 million in cash and a $350 million equity investment – with another $1.4 ...

To watch more expert insights and analysis ... Pfizer, as it competes with the likes of Novo Nordisk and Eli Lilly in the weight loss drug space. 00:43 Speaker B Plus, Nvidia announcing a big ...